What is Cellares?
Cellares is an Integrated Development and Manufacturing Organization (IDMO) dedicated to the automated, large-scale production of cell therapies. The company addresses critical capacity, consistency, and cost challenges inherent in traditional manufacturing models by deploying its proprietary Cell Shuttle and Cell Q platforms. These automated systems, integrated into Cellares' IDMO Smart Factories, ensure end-to-end manufacturing and quality control, promising enhanced process reproducibility, higher manufacturing success rates, and significantly improved throughput compared to conventional approaches. Headquartered in South San Francisco, California, Cellares is expanding its global footprint with facilities in New Jersey, Europe, and Japan, positioning itself as a leader in the next generation of cell therapy production.
How much funding has Cellares raised?
Cellares has raised a total of $662M across 5 funding rounds:
Series A
$18M
Series B
$82M
Series C
$255M
Series D
$257M
Series D
$50M
Series A (2020): $18M with participation from Eclipse Ventures
Series B (2021): $82M led by Decheng Capital, 8VC, Eclipse, and Skyviews Life Science
Series C (2023): $255M supported by KOCH Technology, Bristol-Myers Squibb, and 8VC
Series D (2026): $257M featuring Eclipse Capital Management, BlackRock, Intuitive Growth Ventures, T. Rowe Price, and Gates Frontier
Series D (2026): $50M backed by Prime Radiant Partners
Key Investors in Cellares
Eclipse Capital Management
Eclipse Capital Management is an alternative investment management firm specializing in quantitative, model-driven trading strategies, known for its pioneering approach in managed futures and asset allocation.
BlackRock
BlackRock is a global investment management corporation offering a wide array of investment products and services, managing assets across diverse classes for institutional and individual clients worldwide.
Intuitive Growth Ventures
Intuitive Growth Ventures is a venture capital firm focused on supporting technology startups through funding and strategic guidance, particularly in emerging sectors like AI and Bio-IT.
What's next for Cellares?
The recent major strategic investment in Cellares signals a strong market validation and provides the necessary capital for scaling its innovative manufacturing solutions. This financing is expected to accelerate the expansion of its IDMO Smart Factory network, further enhancing its capacity to serve global biopharmaceutical partners. Cellares is poised to solidify its position as a critical enabler of cell therapy commercialization, driving down production costs and increasing accessibility for advanced therapeutic treatments.
See full Cellares company page
